Introduction {#s5}
============

Schizophrenic disorder affects approximately 1% of the general population ([@CIT0025]) and is associated with major functional impact ([@CIT0017]). The physiopathology of schizophrenia is not well established, but many factors could influence the emergence of this pathology, such as a genetic predisposition ([@CIT0046]), obstetrical complications ([@CIT0014]; [@CIT0004]), or infections ([@CIT0003]). A relationship with pre- or perinatal neurodevelopmental events (such as obstetrical complications or maternal infections) has been found and could be linked to aberrant hypothalamic-pituitary-adrenal (HPA) axis activation during exposure to psychological stress ([@CIT0045]; [@CIT0007]; [@CIT0023]). Study results investigating serum cytokine levels appear to contradict some studies that have found an overactivation of the proinflammatory system or T helper 1 (Th1) system ([@CIT0032]), and others that have found a dysfunction in the normal balance between the proinflammatory system (Th1 system) and the antiinflammatory system or Th2 system ([@CIT0039]). Meta-analyses have been performed ([@CIT0038]; [@CIT0015]) and they showed that certain cytokines increased in acute exacerbations of schizophrenia and could be considered as state-related markers (interleukin \[IL\]-1β; IL-6 or transforming growth factor β \[TGF-β\]), whilst others did not change during acute exacerbation and could be considered as trait markers (IL-12; interferon γ \[IFN-γ\]; tumor necrosis factor α \[TNF-α\] and sIL-2R) ([@CIT0038]).

Currently, antipsychotic drugs are the first choice treatment in schizophrenia. The effect of antipsychotic treatment on the immune system is not yet clear, but preclinical studies have found a possible microglia activation damping effect ([@CIT0029]; [@CIT0059]). Presently, it is not clear whether the kinetics of cytokine levels before and after treatment are caused by antipsychotic drugs or whether they reflect clinical evolution as a state-related marker. To investigate this point, we chose to perform stratification by type of treatment and by diagnosis.

The aim of this meta-analysis was to investigate the impact of antipsychotics on the kinetics of cytokine levels in in vivo schizophrenia studies. A secondary aim was to evaluate the impact of the diagnosis to see whether all antipsychotic drugs had the same impact on the kinetics of cytokine levels. The final aim of this work was to perform a meta-regression analysis including clinical data to assess the putative heterogeneity.

Methods {#s6}
=======

Data Sources and Study Selection Process {#s7}
----------------------------------------

We carried out a search on the MEDLINE and PsycINFO databases in January 2017, without any limits on year of publication, using the key words cytokines or immune inflammation and schizophrenia or first psychotic episode or psychosis. Studies were included if (1) they were published in English in a peer-reviewed journal, (2) they included patients with a diagnosis of schizophrenia based on DSM, III, IV, or V criteria, and (3) they measured in vivo cytokines levels in plasma or serum, before and after antipsychotic treatment. Studies that did not fulfill these 3 criteria were systematically excluded from the analyses. To obtain additional data, an email alert was created after January 2017 on MEDLINE with the same keywords to detect any publications of potential interest. The reference lists of articles identified were reviewed for additional studies. Study selection was performed by one author (B.R.) and verified by another (C.M.).

Data Extraction {#s8}
---------------

When data were not available in the articles, we contacted the corresponding authors (see Acknowledgments) of each included trial by email to improve data collection and obtain the stratified data for each antipsychotic treatment or each diagnosis. If more than one group was available in the article ([@CIT0002]), we used the method recommended by the Cochrane group (Cochrane 2011): M=(N~1~ M~1~+N~2~ M~2~)/(N~1~+N~2~) and SD=√((N~1~-1)SD~1~^2^ +(N~2~-1)SD~2~^2+^(N~1~ \*N~2~/N~1+~N~1~)(M~1~^2+^M~1~^2^-2 M~1~ M~2~))/(N~1~+ N~2~-1) (where N~1~ is the number of patients in the first group assessment, N~2~ is the number of patients in the second group assessment, M~1~ is the mean of the first group, M~2~ is the mean of the second group, SD~1~ is the standard deviation of the first group, and SD~2~ is the standard deviation of the second group). For each study, we thus obtained the means and SD for all cytokine levels before and after treatment. Articles written by a given research group were carefully scrutinized to ensure the absence of redundancy among the populations included in the trials.

A set of clinical variables was defined for the meta-regression analysis. We extracted the duration study (in weeks), the means and SDs for age (age variable), the percentages of females (sex variable), the means and SDs for years of illness (duration of illness variable), the mean age at onset of the disorder (onset disorder variable), and the means and SDs for schizophrenia severity scores before and after treatment (total, positive, negative, and general symptom scores). Data extraction was performed by one author (B.R.) and verified by another (C.M.).

Data Analyses {#s9}
-------------

Data analyses were performed using RevMan, version 5.3 (Copenhagen, Denmark; the Nordic Cochrane Centre, Cochrane Collaboration). Effect sizes consisted in the standardized mean differences (SMD) between cytokine levels before and after treatment or between the schizophrenia severity scale scores for total, positive, negative, or general symptoms before and after treatment. According to Cohen's method, SMDs were calculated as the differences between group means divided by the pooled SDs. All analyses were performed with a random-effect model, which considers both between-study and within-study variability ([@CIT0009]). An effect size was considered significant when the 95% CI excluded 0 and when the *P* \< .05.

Study heterogeneity was estimated with the Q statistic, which was calculated for all analyses and considered significant when *P*\<.1. When a significant level of heterogeneity was reached, the *I*^2^ index, an estimate of the total variation across the studies included due to heterogeneity rather than chance, was determined by the equation *I*^2^=\[(*Q* -- df)/*Q*\] \* 100% ([@CIT0020]). *I*^*2*^ values of 25, 50, and 75 were indicative of mild, moderate, and marked heterogeneity, respectively, between trials. In addition, to ensure that the overall results were not influenced by a single study, leave-1-out sensitivity analyses, performed by repeating the analyses with the consecutive exclusion of each study, were carried out for each analysis when more than 2 studies were included. Results are given in the supplementary Materials. Finally, we conducted more specific secondary analyses involving the primary diagnoses: first psychotic episode, acute exacerbation of schizophrenia, chronic schizophrenia (studies that included in their methods: chronic schizophrenia patients, patients with a duration of illness \>5 years, and no current acute exacerbation of illness were included in our analyses) and resistant schizophrenia (define by an insufficient antipsychotic response or by the Kane's criteria \[[@CIT0026]\]), and the type of antipsychotic treatment used.

Funnel plots, plotting the standard error of each SMD against the SMD calculated for each study included, were drawn up when at least 5 individual studies contributed to an overall result, and their asymmetry was analyzed to assess the possible influence of publication and location biases ([@CIT0018]).

Finally, we conducted meta-regression analyses based on simple linear regression models for assessing the influence of the clinical heterogeneity of the study populations on meta-analysis effect sizes. Regression analyses were performed only when SMDs or heterogeneity were significant and when a reasonable number of data points were available, set at 6 at least.

Results {#s10}
=======

Article Identification Process {#s11}
------------------------------

[Figure 1](#F1){ref-type="fig"} shows the article-selection process and [supplemental Table 1](#sup1){ref-type="supplementary-material"} shows details of included studies. The database search found 1562 articles. Forty-six studies identified by database research and 1 other identified by email alert were included. Of these 47 studies, 41 studies specify in their article that they exclude patients (1) with somatic comorbidity that may explain variations in cytokine levels, (2) with an abnormality in standard physical and biological examinations, and (3) taking a treatment that impacts the immune system.

![Article identification process.](pyy06201){#F1}

All Treatments {#s12}
--------------

All results are summarized in [Table 1](#T1){ref-type="table"}. After treatment, there was a significant decrease in the following: IL-1 β levels (n=7 studies; test for overall effect: SMD=-0.40, 95% CI: -0.58 to -0.22, *P*\<.0001; test for heterogeneity: χ^2^=4.5, *P*=.61, I^2^=0 %), and IFN-γ levels (n=8 studies; test for overall effect: SMD=-0.38, 95% CI: -0.67 to -0.09, *P*=.01; test for heterogeneity: χ^2^=23.02, *P*=.002, I^2^=70 %). There was a statistical trend for a decrease in IL-6 levels (n=21 studies; test for overall effect: SMD=-0.22, 95% CI: -0.47 to 0.03, *P*=.08; test for heterogeneity: χ^2^=107.13, *P*\<.0001, I^2^=81 %), in TNF-α levels (n=19 studies; test for overall effect: SMD=-0.32, 95% CI: -0.65 to 0.02, *P*=.07; test for heterogeneity: χ^2^=131.95, *P*\<.0001, I^2^=86 %), and in IL-4 levels (n=7 studies; test for overall effect: SMD=-0.47, 95% CI: -0.99 to 0.06, *P*=.08; test for heterogeneity: χ^2^=72.9, *P*\<.0001, I^2^=92 %). After treatment, a significant increase was observed in sTNF-R2 levels (n=3 studies; test for overall effect: SMD=0.94, 95% CI: 0.52--1.36, *P*\<.0001; test for heterogeneity: χ^2^=0.49, *P*=.78, I^2^=0 %) and in sIL-2R levels (n=11 studies; test for overall effect: SMD=0.26, 95% CI: 0.03--0.49, *P*=.03; test for heterogeneity: χ^2^=16.09, *P*=.1, I^2^=38 %).

###### 

Results for all Treatments

  Cytokine   Numbers of Studies Included   Numbers of Patients before/after Treatments   SMD     95% CI       *P* value   Χ^2^     *P* value   I^2^ (%)   References
  ---------- ----------------------------- --------------------------------------------- ------- ------------ ----------- -------- ----------- ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  IL-1 β     7                             241/241                                       -0.40   -.58; -.22   \<.01       4.5      .61         0          Theodoropoulou et al., 2001; [@CIT0030], [@CIT0031]; [@CIT0019]; [@CIT0051], 2009; [@CIT0050]
  IL-6       21                            763/784                                       -0.22   -.47; 0.03   .08         107.13   \<.01       81         [@CIT0044]; [@CIT0013]; [@CIT0047]; [@CIT0030], [@CIT0033], [@CIT0031]; [@CIT0037], [@CIT0036]; [@CIT0057]; [@CIT0043]; [@CIT0022]; [@CIT0024]; [@CIT0035]; [@CIT0034]; [@CIT0002]; [@CIT0011]; [@CIT0051]; [@CIT0019]; [@CIT0050]; [@CIT0042]; [@CIT0027]
  sIL-6 R    4                             84/84                                         -0.17   -.72; 0.37   .53         8.37     .04         64         [@CIT0036], [@CIT0037]; Muller et al. 1997
  IL-8       4                             144/144                                       -0.17   -.40; 0.06   .14         0.14     .99         0          Maes et al. 2002; [@CIT0057]; [@CIT0034]; [@CIT0019];
  IL-12      4                             121/121                                       0.13    -.34; 0.60   .58         9.05     .03         67         Crespo-Facorro et al. 2008; [@CIT0030], 2002; [@CIT0050]
  TNF-α      19                            583/579                                       -0.32   -.65; 0.02   .07         131.95   \<.01       86         [@CIT0044]; Monteleone et al., 1997; Hinze-Selch et al., 2000; [@CIT0047]; Theodoropoulou et al., 2001; [@CIT0043]; Baptista et al., 2007; [@CIT0022]; Sarandol et al., 2007; [@CIT0033]; [@CIT0035]; [@CIT0034]; [@CIT0001]; [@CIT0051], 2009; [@CIT0019]; [@CIT0042]; [@CIT0050]; [@CIT0027]
  sTNF-R1    5                             91/91                                         0.35    -.16; 0.86   .18         11.15    .02         64         Hinze-Selch et al. 2000; Muller et al. 2004; Pollmacher et al. 1996; [@CIT0047]; [@CIT0050]
  sTNF-R2    3                             49/49                                         0.94    0.52; 1.36   \<.01       0.49     .78         0          [@CIT0044]; Hinze-Selch et al., 2000; [@CIT0047]
  IL-2       10                            311/311                                       -0.31   -.03; 0.40   .39         149.82   \<.01       94         [@CIT0031], [@CIT0030], [@CIT0033]; Theodoropoulou et al. 2001; [@CIT0057]; [@CIT0043]; [@CIT0022]; [@CIT0001]; [@CIT0019]; [@CIT0027]
  sIL-2 R    11                            263/263                                       0.26    0.03; 0.49   .03         16.09    .10         38         Maes et al., 1995; [@CIT0044], 1995; Müller et al., 1997; Schwarz et al., 1998; Hinze-Selch et al., 2000; [@CIT0047]; Muller et al., 2004; Sirota et al., 2005; [@CIT0024]; Szymona et al., 2017
  IL-17      3                             248/248                                       0.02    -.29; 0.34   .88         5.82     .05         66         [@CIT0002]; [@CIT0011]; Noto et al. 2014
  IL-1 RA    6                             131/131                                       -0.03   -.48; 0.42   .89         16.35    .006        69         Pollmacher et al. 1996; [@CIT0036], [@CIT0037]; Sirota et al. 2005; [@CIT0024]; [@CIT0050]
  TGF- β     5                             303/303                                       -0.20   -.61; 0.21   .35         21.85    .0002       82         [@CIT0032], [@CIT0033]; [@CIT0035]; [@CIT0002]; [@CIT0050]
  IL-10      8                             210/210                                       0.09    -.40; 0.57   .72         39.09    \<.01       82         Maes et al. 2002; [@CIT0034]; [@CIT0043]; Noto et al. 2014; [@CIT0001]; [@CIT0019]; [@CIT0050]; [@CIT0027]
  IFN-γ      8                             380/380                                       -0.38   -.67; -.09   .01         23.02    .002        70         [@CIT0002]; [@CIT0011]; [@CIT0019]; [@CIT0050]; [@CIT0027]; [@CIT0030], [@CIT0033], [@CIT0032]
  IL-4       7                             399/399                                       -0.47   -.99; 0.06   .08         72.90    \<.01       92         [@CIT0002]; [@CIT0019]; [@CIT0033], [@CIT0032]; [@CIT0042]; [@CIT0050]; Szymona et al., 2017
  IL-23      2                             68/68                                         -0.01   -.35; 0.32   .94         0.20     .65         0          Borovcanin et al. 2015; [@CIT0050]

Abbreviations: I^2^, *I*^2^ index, an estimate of the total variation across the studies included; IFN, interferon; IL, interleukin; sIL-6 R, soluble interleukine 6 receptor; sIL-2 R, soluble interleukine 2 receptor; SMD, standard mean difference; sTNF-R1, soluble tumor necrosis factor receptor 1; sTNF-R2, soluble tumor necrosis factor receptor 2; TNF, tumor necrosis factor; TGF, transforming growth factor.

Meta-regression analyses showed a significant positive correlation between IL-6 SMD before and after treatment and positive symptom score SMDs before and after treatment (r=0.81; *P*=.001) ([Figure 2](#F2){ref-type="fig"}), and a statistical trend between IL-10 SMDs before and after treatment and positive symptom score SMDs before and after treatment (r=0.76; *P*=.08). No other significant correlation was found in the other meta-regression analyses.

![Correlation between interleukin (IL)-6 standard mean difference (SMD) and positive symptoms scale SMD (r=0.81; *P*=.001). We found an association between the decrease of IL-6 level and the decrease of positive symptoms after antipsychotic treatment.](pyy06202){#F2}

Stratification by Treatment {#s13}
---------------------------

Following risperidone treatment ([supplemental Table 2](#sup1){ref-type="supplementary-material"}), there was a significant decrease in the following: IL-1 β levels (n=4 studies; test for overall effect: SMD=-0.47, 95% CI: -0.69 to -0.25, *P*\<.0001; test for heterogeneity: χ^2^=0.80, *P*=.85, I^2^=0 %), IL-6 levels (n=7 studies; test for overall effect: SMD=-0.22, 95% CI: -0.39 to -0.05, *P*=.01; test for heterogeneity: χ^2^=4.46, *P*=.61, I^2^=0 %), IL-2 levels (n=3 studies; test for overall effect: SMD=-0.42, 95% CI: -0.78 to -0.06, *P*=.02; test for heterogeneity: χ^2^=0.8, *P*=.67, I^2^=0 %), IL-10 levels (n=2 studies; test for overall effect: SMD=-0.83, 95% CI: -1.22 to -0.44, *P*\<.0001; test for heterogeneity: χ^2^=0.02, *P*=.89, I^2^=0 %), and IL-4 levels (n=3 studies; test for overall effect: SMD=-0.67, 95% CI: -0.99 to -0.34, *P*\<.0001; test for heterogeneity: χ^2^=0.25, *P*=.88, I^2^=0 %). A significant increase in IL-12 levels (n=2 studies; test for overall effect: SMD=0.66, 95% CI: 0.18 to 1.14, *P*=.007; test for heterogeneity: χ^2^=0.25, *P*=.62, I^2^=0 %) was also found after risperidone treatment.

Following olanzapine treatment ([supplemental Table 3](#sup1){ref-type="supplementary-material"}), there was a significant decrease in IL-2 levels (n=2 studies; test for overall effect: SMD=-1.17, 95% CI: -2.32 to -0.03, *P*=.05; test for heterogeneity: χ^2^=4.08, *P*=.04, I^2^=76 %) and IFN-γ levels (n=2 studies; test for overall effect: SMD=-1.30, 95% CI: -2.15 to -0.46, *P*=.003; test for heterogeneity: χ^2^=0.16, *P*=.69, I^2^=0 %).

After quetiapine treatment ([supplemental Table 4](#sup1){ref-type="supplementary-material"}), no significant increase or decrease in cytokine levels was found.

After aripiprazole treatment ([supplemental Table 5](#sup1){ref-type="supplementary-material"}), a statistical trend toward a decrease in IL-4 levels (n=2 studies; test for overall effect: SMD=-0.53, 95% CI: -1.15 to 0.09, *P*=.09; test for heterogeneity: χ^2^=0.28, *P*=.60, I^2^=0 %) was found. A significant increase in IL-10 levels (n=2 studies; test for overall effect: SMD=0.92, 95% CI: 0.28--1.56, *P*=.005; test for heterogeneity: χ^2^=0.78, *P*=.38, I^2^=0 %) was also found after aripiprazole.

After clozapine treatment ([supplemental Table 6](#sup1){ref-type="supplementary-material"}), there was a significant increase in the following: sTNF-R1 levels (n=2 studies; test for overall effect: SMD=0.89, 95% CI: 0.43--1.36, *P*=.0002; test for heterogeneity: χ^2^=0.20, *P*=.65, I^2^=0 %), sTNF-R2 levels (n=2 studies; test for overall effect: SMD=0.98, 95% CI: 0.51--1.46, *P*\<.0001; test for heterogeneity: χ^2^=0.36, *P*=.55, I^2^=0 %), and sIL-2 R levels (n=3 studies; test for overall effect: SMD=0.62, 95% CI: 0.08--1.16, *P*=.02; test for heterogeneity: χ^2^=3.21, *P*=.20, I^2^=38 %). There was also a statistical trend toward an increase in IL-6 levels (n=3 studies; test for overall effect: SMD=0.44, 95% CI: -0.03 to 0.92, *P*=.07; test for heterogeneity: χ^2^=2.82, *P*=.24, I^2^=29 %).

After haloperidol treatment ([supplemental Table 7](#sup1){ref-type="supplementary-material"}), a significant decrease in IL-2 levels was observed (n=2 studies; test for overall effect: SMD=-0.75, 95% CI: -1.11 to -0.38, *P*\<.0001; test for heterogeneity: χ^2^=0.06, *P*=.80, I^2^=0 %).

Stratification by Diagnosis {#s14}
---------------------------

Among first episode psychosis (FEP) patients ([supplemental Table 8](#sup1){ref-type="supplementary-material"}), after treatment, there was a significant decrease in IL-1 β levels (n=4 studies; test for overall effect: SMD=-0.36, 95% CI: -0.63 to -0.10, *P*=.007; test for heterogeneity: χ^2^=4.14, *P*=.25, I^2^=27 %), in IL-6 levels (n=5 studies; test for overall effect: SMD=-0.36, 95% CI: -0.57 to -0.16, *P*=.0004; test for heterogeneity: χ^2^=4.61, *P*=.33, I^2^=13 %), and in IL-4 levels (n=3 studies; test for overall effect: SMD=-0.45, 95% CI: -0.75 to -0.15, *P*=.003; test for heterogeneity: χ^2^=3.38, *P*=.18, I^2^=41 %).

In acute exacerbations of schizophrenia ([supplemental Table 9](#sup1){ref-type="supplementary-material"}), after treatment, there was a significant decrease in IL-1 β levels (n=6 studies; test for overall effect: SMD=-0.41, 95% CI: -0.59 to -0.22, *P*\<.0001; test for heterogeneity: χ^2^=4.55, *P*=.47, I^2^=0 %), in IL-6 levels (n=14 studies; test for overall effect: SMD=-0.44, 95% CI: -0.74 to -0.15, *P*=.003; test for heterogeneity: χ^2^=78.67, *P*\<.00001, I^2^=83 %), in sIL-6 R levels (n=2 studies; test for overall effect: SMD=-0.51, 95% CI: -0.90 to -0.12, *P*=.01; test for heterogeneity: χ^2^=0.86, *P*=.35, I^2^=0 %), in TNF-α levels (n=12 studies; test for overall effect: SMD=-0.46, 95% CI: -0.89 to -0.03, *P*=.04; test for heterogeneity: χ^2^=103.50, *P*\<.00001, I^2^=89 %), and in IFN-γ levels (n=7 studies; test for overall effect: SMD=-0.41, 95% CI: -0.73 to -0.09, *P*=.01; test for heterogeneity: χ^2^=22.62, *P*\<.0001, I^2^=73 %).

In chronic schizophrenia patients ([supplemental Table 10](#sup1){ref-type="supplementary-material"}), after treatment, only 2 analyses were performed (IL-6 and IL-1 RA), and they did not show any significant difference in cytokine levels.

In resistant schizophrenia patients ([supplemental Table 11](#sup1){ref-type="supplementary-material"}), after treatment, a significant increase was observed in IL-6 levels (n=3 studies; test for overall effect: SMD=0.57, 95% CI: 0.20--0.95, *P*=.003; test for heterogeneity: χ^2^=1.30, *P*=.52, I^2^=0 %) and in sIL-2 R levels (n=2 studies; test for overall effect: SMD=0.85, 95% CI: 0.39--1.32, *P*=.0003; test for heterogeneity: χ^2^=0.05, *P*=.83, I^2^=0 %).

Discussion {#s15}
==========

This present meta-analysis shows that the levels of some proinflammatory cytokines decreased after treatment (significant decrease in IL-1 β and IFN-γ levels and a statistical trend toward a decrease in IL-6 and TNF-α levels) and that some antiinflammatory cytokine levels increased after treatment (significant increase in sTNF-R2 and sIL2-R levels). We found that IL-6 level SMDs were correlated to the positive symptoms score SMDs. We also found that, in some cases, the kinetics of cytokine levels could be impacted by diagnosis and/or the type of antipsychotic used.

The main difference from previous meta-analysis on the same topic ([@CIT0038]; [@CIT0054]; [@CIT0015]) is the number of studies included and, therefore, the statistical power. We have included 47 studies whereas other meta-analysis included between 12 and 23 studies. A possible explanation of this difference was a difference in the methodology. For example, [@CIT0015] had included only acutely ill patients in their analysis. Compared with other meta-analysis ([@CIT0038]; [@CIT0054]; [@CIT0015]), inclusion of new studies permit us to perform new comparisons for cytokine levels from other research such as IL-8, IL-23, sTNF-R1, sTNF-R2, which were not previously tested. Many analyses were performed with significantly more studies. For example, for IL-8 level, only 2 studies were included by [@CIT0054], whereas we included 8 studies or for TNF-α level with 3, 6, and 9 studies included respectively in [@CIT0038]; [@CIT0015] and [@CIT0054], whereas we included 19 studies. Compared with other meta-analysis ([@CIT0054]; [@CIT0015]), our results are quite similar, but as we included a larger number of studies, we obtained a larger statistical database. Therefore, we found some difference: we did not find that IL-12 levels were impacted by treatment as contrary to 3 other meta-analyses ([@CIT0038]; [@CIT0054]; [@CIT0015]) that found an IL-12 level increase. The significant result found in these 2 meta-analyses could merely be due to the small number of studies included (respectively 2 and 3 studies). We found a significant decrease in IFN-γ level like [@CIT0054] counter to [@CIT0015] and [@CIT0038]. Finally, other meta-analyses ([@CIT0038]; [@CIT0054]; [@CIT0015]) found II-6 level decreased while our results underlined a statistical trend to decrease. It is important to note that in this analysis, 763 patients were included, whereas only 164 and 521 patients were included in [@CIT0038] and [@CIT0015], respectively.

Our results show a trend to a normalization of the dysfunction in the normal balance between the proinflammatory system (Th1 system) and the antiinflammatory system or Th2 system ([@CIT0039]). We found that antipsychotic treatment had an antiinflammatory effect, with a decrease in proinflammatory cytokine levels such as IL-1 β, IFN-γ, IL-6, and TNF-α and an increase in antiinflammatory cytokine levels such as sTNF-R2 or sIL2-R. The increase of sTNF-R2 levels after treatment could illustrate the possible antiinflammatory impact of treatment. In a homeostatic situation, it seems that the production of soluble receptors is auto-regulated by the cytokines themselves ([@CIT0055]; [@CIT0008]). We hypothesize that, in schizophrenic patients, the homeostasis situation is disrupted and causes a disturbance of this retro-control. This could be reversed through antipsychotic medications. The possible antiinflammatory involvement could be illustrated by a recent study ([@CIT0021]) using positron emission tomography and radioligands that bind to the 18-kDa translocator protein that shows a direct interaction between antipsychotic medication and microglial activation in medicated patients with schizophrenia. The antiinflammatory effect of antipsychotic treatment may produce microglial activation ([@CIT0021]). There are 2 possible explanations for this normalization: the direct impact of antipsychotic treatment on the immune system or the indirect effect of antipsychotic treatment on the immune system by the improvement of the clinical symptoms of schizophrenia.

Moreover, we found an association between IL-6 level SMDs and positive symptom schizophrenia score SMDs. A similar correlation between evolution in the general symptom schizophrenia score and IL-6 levels was also found in 2 studies including schizophrenia patients ([@CIT0013]; [@CIT0043]). Positive correlations were also found between positive symptoms and IL-6 level in one study including ARMS patients ([@CIT0053]) and one other study including war veterans with schizophrenia ([@CIT0010]). Another association was found between levels of IL-6 mRNA and positive symptoms in schizophrenia patients ([@CIT0005]). At the onset of psychosis, a dysfunction of the HPA axis was found in relation to social stress ([@CIT0007]). Our hypothesis is that microglia activation leads to ventral hippocampus activation, which is also involved in context-related behaviors ([@CIT0016]; [@CIT0023]). This activation leads to an overactivation of the ventral tegmental area dopaminergic neuron by activation of the nucleus accubens, which downregulates pallidum ventral inhibition ([@CIT0016]; [@CIT0023]). Antipsychotic treatment, by dopaminergic antagonism, could restore the axis balance. IL-6 levels have also been found to decrease in other psychiatric disorders such as major depressive disorder between acute and remission states ([@CIT0013]). In healthy humans, acute psychological stress showed an increased IL-6 plasmatic level ([@CIT0052]). Positive symptoms could therefore be considered an important stress factor independently from the psychiatric diagnosis (e.g., infections associated with immune proinflammatory activation). Theoretically, a glucocorticoid feedback from the inhibitory effects on nuclear factor κβ could enable return to homeostasis after stressor cessation ([@CIT0045]), but it could be impaired in mental illness ([@CIT0049]). IL-6 levels could be considered a stress marker and reflect HPA overactivation ([@CIT0045]). IL-6 level normalization could be a marker of illness equilibration and therefore could be used in clinical practice. No other association between cytokine kinetics and demographic variables was found. In particular, we did not find an association between the duration of the study (and therefore the duration of the treatment) and the MDS of cytokine levels. This result was not consistent with the outcome of another study ([@CIT0051]) that investigated the 6-month kinetics of cytokines in patients with schizophrenia under risperidone. In this study ([@CIT0051]), researchers found an initial decrease in IL-6 and IL-1β levels in the first 2 months and a return to baseline after 6-month treatment. In our analysis, most studies included a duration of treatment between 4 and 10 weeks (only 3 studies had a longer duration), which could explain the absence of result of the meta-regression between cytokines SMD and duration of the study. To explain the increase in proinflammatory cytokine levels with long-term treatment, [@CIT0051] hypothesized that increasing BMI may increase the proinflammatory response. Unfortunately, we were unable to perform an analysis including BMI because of a lack of available data, which did not allow us to establish a relationship between proinflammatory cytokine levels and BMI.

We found that the different types of antipsychotic treatment could influence cytokine levels differently, as with IL-2, IL-10, IFN-γ, or IL-12. One hypothesis is that all antipsychotic drugs have pharmacological specifications, notably on the serotoninergic and noradrenergic systems, which could impact the HPA axis differently and therefore impact the liberation of cytokines in stress response differently ([@CIT0045]). However, other factors could impact results, such as tobacco use, which could decrease IL-2 and IL-6 levels ([@CIT0058]), or body mass index (BMI). Obesity has been shown to increase levels of proinflammatory cytokines, such as TNF-α, IFN-γ, or IL-1 β, and decrease levels of antiinflammatory cytokines such as IL-1RA ([@CIT0006]; [@CIT0048]). Some treatments like clozapine, olanzapine, or quetiapine are known to increase weight and cause metabolic syndromes and could cause an increase of proinflammatory cytokine like IL-6. This modification could explain the absence of a significant decrease of IL-6 level after these 3 treatments in our analysis. Baseline IL-6 levels have also been shown to be predictors of the increase in total and LDL cholesterol and therefore a potential predictor of metabolic syndrome ([@CIT0012]). The meta-analyses concerning aripiprazole treatment, which causes less weight gain than other antipsychotic treatments ([@CIT0041]), are difficult to interpret due to a lack of data. This meta-analysis confirms the need to consider BMI in different studies investigating the immune system. Another point illustrated by this meta-analysis stratification is a general decrease in heterogeneity when the different antipsychotic treatments are considered separately. For example, the IL-6 level SMD analysis found an I^2^ at 81% for all treatment analyses, whereas it was 0% for risperidone or olanzapine analyses. This decrease in heterogeneity enables an improvement in analysis quality and therefore in the interpretation of results.

We found a possible implication of the diagnosis in the evolution of cytokine levels. We found some differences between FEP and acute exacerbation of schizophrenia, notably on TNF-α and IFN-γ levels, which show a decrease after treatment in acute episodes but not in FEP. It is important to note that the difference in TNF-α levels in acute episodes is underpinned by only 2 studies ([@CIT0033]; [@CIT0001]). If we exclude one of these 5 studies, the result loses its significance. For IFN-γ levels, interpretation of these 2 results was difficult because of heterogeneity. IL-6 levels showed a decrease after treatment in FEP and in acute exacerbation of schizophrenia but not in chronic schizophrenia or resistant schizophrenia. It is important to note that heterogeneity in the acute exacerbation of schizophrenia is based on only one study ([@CIT0033]); its exclusion causes an I^2^ decrease from 83% to 7% but did not change the significance of the result. Our explanation for these results is that the positive symptom score at baseline was low in chronic schizophrenia studies ([@CIT0024]; [@CIT0050]), so it is possible that the HPA axis was not activated as in acute schizophrenia or in FEP. A similar result was also found in ultra-high-risk schizophrenia, which had positive symptoms significantly lower than in FEP, with an IL-6 level lower than in FEP ([@CIT0028]). These results confirm that IL-6 could be a stress marker, which could reflect HPA activation, and that positive symptoms could be potential stressors that activate this axis. Another factor that could take part in the kinetics of IL-6 levels is illness duration with a possible habituation to psychotic symptoms. For example, [@CIT0002] investigated IL-6 levels and found an increase in FEP compared with acute schizophrenia (27.85 pg/mL and 16.25 pg/mL, respectively).

Our meta-analysis has several limitations. First, there is a great heterogeneity across analyses, especially in all treatment analyses that are not explained by meta-regression, except for IL-6 levels. A second limitation was the small number of studies included in the analyses, notably in the stratified analyses, which could be responsible for poor statistical power. A final limitation was that the studies analyzed were performed in blood and not in CSF, which could have a more direct link with the CNS. The influence of certain clinical factors such as obesity ([@CIT0056]; [@CIT0040]) could explain the observed variations between peripheral and central cytokines and could explain why peripheral investigation is not necessarily associated with CNS inflammation. The different results obtained in this meta-analysis on peripheral cytokine levels should therefore be interpreted with caution, and further studies on the impact of antipsychotic treatments in CSF cytokine levels may be useful in confirming our results.

In conclusion, this meta-analysis provides evidence for an antiinflammatory effect of antipsychotic treatment. IL-6 levels were found to be stress markers directly correlated with the evolution of psychotic symptoms, and they could be used as markers for illness equilibration. The type of antipsychotic treatment used and/or the diagnosis impact cytokine levels differently and explain in part the heterogeneity found in global analyses.
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